Bristol Myers Squibb (BMS) is to acquire 2seventy bio, its partner in developing multiple myeloma drug Abecma, for about $286m. The deal follows a turbulent three years for 2seventy bio, which recorded net losses of $217.57m in 2023 and saw 54% of its workforce cut in a restructuring and refocusing drive. The acquisition is expected to close in Q2 2025.
Navigating Cybersecurity Frameworks – CISO Resource Guide
The role of the Chief Information Security Officer (CISO) is crucial amid evolving cyber threats. Selecting the right cybersecurity framework aligns risk management with organizational
%20CISO%E2%80%99s%20Core%20Focus.webp?w=0&resize=0,0&ssl=1 "Identity and Access Management (IAM)")
